Reduction of Early mortaLITY in HIV-infected African adults and children starting antiretroviral therapy: REALITY trial. (360G-Wellcome-096465_Z_11_Z)
The principalresearch question is how best to reduce excess early mortality in African HIV-infected adults andchildren initiating ART. Reasons for high early mortality are multi-factorial, including high rates ofco-infections (TB, bacterial infections, fungal/protozoal infections, parasites), immunereconstitution inflammatory syndrome (IRIS), malnutrition and advanced HIV infection. Severalinterventions might therefore reduce early mortality in HIV-infected patients startingART with low CD4, and could form part of a highly effective integrated care "bundle".
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 793577 |
Applicant Surname | Gibb |
Approval Committee | Joint Global Health Trials Committee |
Award Date | 2011-05-16T00:00:00+00:00 |
Financial Year | 2010/11 |
Grant Programme: Title | Joint Global Health Trials Award |
Internal ID | 096465/Z/11/Z |
Lead Applicant | Prof Diana Gibb |
Partnership Name | Joint Global Health Trials |
Partnership Value | 793577 |
Planned Dates: End Date | 2015-06-30T00:00:00+00:00 |
Planned Dates: Start Date | 2012-01-01T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | South West |